The Centers for Medicare & Medicaid Services will not cover drugs when exclusively used for weight loss, like Ozempic or Wegovy, the Trump administration announced.

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce weight.

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Centers for Medicare and Medicaid (CMS) announced Friday it will not be finalizing a rule proposed by the Biden ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...

Tremfya achieved an impressions share of voice (SOV) of 3.35%, generating 2.1 billion total impressions. While the brand held ...